Bitesize Bio's Vicki Ronaldson this week says that "despite the temptation to play down past academic pursuits amongst more corporate peers, a look at the top level management, or even the board, of any global life science or technology company will reveal a high percentage of PhDs, all of whom started out at the bench." But, she says, transitioning from academic research to the corporate world can be tough.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.